Drug Resistance Updates
Volume 9, Issue 1 , Pages 74-86 , February 2006

Microtubule-targeting agents in angiogenesis: Where do we stand?

Received 2 April 2006 ,Revised 19 April 2006 ,Accepted 19 April 2006.

References 

  1. Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C, et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 2002;532:256–260
  2. Andre N, Meille C. Taxanes in paediatric oncology: and now?. Cancer Treat. Rev. 2006;32:65–73
  3. Aneja R, Lopus M, Zhou J, Vangapandu SN, Ghaleb A, Yao J, et al Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res. 2006;66:3782–3791
  4. Avramis IA, Kwock R, Avramis VI. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res. 2001;21:2281–2286
  5. Banerjee A, Luduena RF. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J. Biol. Chem. 1992;267:13335–13339
  6. Bayless KJ, Davis GE. Microtubule depolymerization rapidly collapses capillary tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho. J. Biol. Chem. 2004;279:11686–11695
  7. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996;2:1843–1849
  8. Bender JG, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodelling and clinical resistance to antiangiogenic therapy. Drug Resist. Updat. 2004;7:289–300
  9. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer. 2003;3:401–410
  10. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342–4346
  11. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. (U.S.A.). 2003;100:12917–12922
  12. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 2002;62:6938–6943
  13. Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin. Cancer Res. 2006;12:1760–1767
  14. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–1886
  15. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: “addictive” targets, mulit-targeted drugs, new drug combinations. Drug Resist. Updat. 2005;8:183–197
  16. Broxterman HJ, Lankelma J, Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist. Updat. 2003;6:111–127
  17. Burkhart CA, Kavallaris M, Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta. 2001;1471:O1–O9
  18. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, et al Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol. 2000;18:1212–1219
  19. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002;62:6831–6836
  20. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  21. Carre, M., Braguer, D., in press. Microtubule damaging agents and apoptosis. In: Fojo, T. (Ed.). Microtubules in Health and Disease. Humana Press.
  22. Casanova M, Ferrari A, Bisogno G, Merks JH, De Salvo GL, Meazza C, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer. 2004;101:1664–1671
  23. Chang AY, Boros L, Asbury R, Hui L, Rubins J. Dose-escalation study of weekly 1-h paclitaxel administration in patients with refractory cancer. Semin. Oncol. 1997;24:69–71
  24. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann. Oncol. 2006;17:232–238
  25. Damber, J.E., Vallbo, C., Albertsson, P., Lennernas, B., Norrby, K., 2005. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother. Pharmacol. 1–7 [Epub ahead of print].
  26. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 2002;62:7247–7253
  27. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry. 1997;36:3554–3562
  28. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell. 2003;3:497–509
  29. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res. 2004;24:1759–1763
  30. Eichhorn ME, Strieth S, Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist. Updat. 2004;7:125–138
  31. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist. 2005;10:665–685
  32. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res. 2005;65:9021–9028
  33. Ettenson DS, Gotlieb AI. Centrosomes, microtubules, and microfilaments in the reendothelialization and remodeling of double-sided in vitro wounds. Lab. Invest. 1992;66:722–733
  34. Farinelle S, Malonne H, Chaboteaux C, Decaestecker C, Dedecker R, Gras T, et al. Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J. Pharmacol. Toxicol. Meth. 2000;43:15–24
  35. Fennelly D, Aghajanian C, Shapiro F, O’Flaherty C, McKenzie M, O’Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 1997;15:187–192
  36. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971;285:1182–1186
  37. Folkman J, Kalluri R. Cancer without disease. Nature. 2004;427:787
  38. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel+cisplatin+granulocyte colony-stimulating factor versus low-dose paclitaxel+cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J. Clin. Oncol. 2001;19:1088–1095
  39. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 2001;21:93–102
  40. Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin. Cancer Res. 2003;9:3476–3485
  41. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 2001;7:427–436
  42. Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462–2467
  43. Gobitti C, Franchin G, Minatel E, Gigante M, Basso B, Bujor L, et al. Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: a phase I study. Oncol. Rep. 2005;14:1647–1653
  44. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. (U.S.A.). 2001;98:11737–11742
  45. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer. 2003;104:121–129
  46. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin. Oncol. 1999;26:28–31
  47. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J. Clin. Oncol. 2005;23:5983–5992
  48. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis. 1999;3:147–158
  49. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64:1570–1574
  50. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000;105:1045–1047
  51. Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R, et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int. J. Oncol. 2002;21:417–425
  52. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res. 2004;64:8249–8255
  53. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br. J. Cancer. 2001;84:290–295
  54. Honore S, Pasquier E, Braguer D. Understanding microtubule dynamics for improved cancer therapy. Cell. Mol. Life Sci. 2005;62:3039–3056
  55. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol. Cancer Ther. 2002;1:1191–1200
  56. Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 2003;23:1433–1440
  57. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350:2335–2342
  58. Iwahana M, Utoguchi N, Mayumi T, Goryo M, Okada K. Drug resistance and P-glycoprotein expression in endothelial cells of newly formed capillaries induced by tumors. Anticancer Res. 1998;18:2977–2980
  59. Jansen RP. mRNA localization: message on the move. Nat. Rev. Mol. Cell. Biol. 2001;2:247–256
  60. Jeremic B, Milicic B, Acimovic L, Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with early-stage (I/II) non-small-cell lung cancer: long-term results of a phase II study. J. Clin. Oncol. 2005;23:6873–6880
  61. Jeremic B, Milicic B, Acimovic L, Milisavljevic S. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study. J. Clin. Oncol. 2005;23:1144–1151
  62. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents. 2002;2:1–17
  63. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer. 2004;4:253–265
  64. Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, et al. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest. 2005;23:13–18
  65. Kamath AV, Chang M, Lee FY, Zhang Y, Marathe PH. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Cancer Chemother. Pharmacol. 2005;56:145–153
  66. Kamath K, Wilson L, Cabral F, Jordan MA. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 2005;280:12902–12907
  67. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2002;2:727–739
  68. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 1991;13:31–36
  69. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000;21:505–515
  70. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer. 2004;4:423–436
  71. Klauber N, Parangi S, Flynn E, Hamel E, D’Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57:81–86
  72. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000;105:R15–R24
  73. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 2002;8:221–232
  74. Kruckzynski, A., Astruc, J., Chazottes, E., Berrichon, G., Ricome, C., Dejean, C., Duflos, A., Fahy, J., Hill, B.T., 2003. Vinflunine, the latest Vinca alkaloid in clinical development, exhibits superior antiangiogenic activity relative to vinorelbine and its derivatives. In: Proceedings of the AACR-NCI-EORTC 15, #B22 (Abstract).
  75. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model. J. Invest. Dermatol. 2003;120:476–482
  76. Kwon HJ, Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, et al. Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells. Jpn. J. Cancer Res. 2002;93:417–425
  77. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 1999;14:31–36
  78. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell. Mol. Med. 2002;6:1–12
  79. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580–584
  80. Lobert S, Frankfurter A, Correia JJ. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity. Cell Motil. Cytoskelet. 1998;39:107–121
  81. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001;7:1194–1201
  82. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3:363–375
  83. Malingre MM, Beijnen JH, Schellens JH. Oral delivery of taxanes. Invest. New Drugs. 2001;19:155–162
  84. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002;62:2731–2735
  85. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001;97:3658–3661
  86. Mancuso, P., Colleoni, M., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R.S., Bertolini, F., in press. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood.
  87. Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, et al. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood. 2003;102:4399–4406
  88. Massacesi C, Marcucci F, Boccetti T, Battelli N, Pilone A, Rocchi MB, et al. Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. J. Exp. Clin. Cancer Res. 2005;24:43–48
  89. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int. J. Cancer. 2005;113:490–498
  90. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res. 2003;63:1534–1537
  91. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 2001;19:1195–1206
  92. Miller, K.D., Sweeney, C.J., Sledge, G. W., Jr., 2005a. Can tumor angiogenesis be inhibited without resistance? In: Clauss, C., Breier, G. (Eds.). Mechanisms of Angiogenesis. Exs, Birkhauser, pp. 95–112.
  93. Miller, K.D., Wang, M. Gralow, J., Dickler, M., Cobleigh, M.A., Perez, E.A., Shenkier, T.N., Davidson, N.E., 2005b. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 41 (Symposium).
  94. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell’Agnola C, Gobbi A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001;61:4341–4344
  95. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist. Updat. 2003;6:355–361
  96. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003;21:3955–3964
  97. Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast. 2005;14:466–479
  98. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 1996;14:1858–1867
  99. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res. 2006;12:1839–1849
  100. Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004;64:821–824
  101. Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, et al. Metronomic ABI-007 therapy: antiangiogenic and antitumor activity of a nanoparticle albumin-bound paclitaxel. Proc. Am. Assoc. Cancer Res. 2005;46:2988;(Abstract)
  102. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 2001;61:2183–2188
  103. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol. Cancer Ther. 2004;3:1301–1310
  104. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 2005;65:2433–2440
  105. Peifer C, Stoiber T, Unger E, Totzke F, Schachtele C, Marme D, et al. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J. Med. Chem. 2006;49:1271–1281
  106. Pourroy B, Honore S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, et al. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res. 2006;66:3256–3263
  107. Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, et al. IDN 5390: an oral taxane candidate for protracted treatment schedules. Br. J. Cancer. 2003;88:965–972
  108. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat. Rev. Cancer. 2002;2:826–835
  109. Rathmann J, Leopold KA, Rigas JR. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results. Semin. Radiat. Oncol. 1999;9:130–135
  110. Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J. Cell. Mol. Med. 2004;8:294–300
  111. Ribatti D, Guidolin D, Conconi MT, Nico B, Baiguera S, Parnigotto PP, et al. Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene. 2003;22:6458–6461
  112. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. (U.S.A.). 2001;98:12485–12490
  113. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin. Cancer Res. 2003;9:2335–2341
  114. Seidman AD. Will weekly work? Seems to be so. J. Clin. Oncol. 2005;23:5873–5874
  115. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 2005;4:2001–2007
  116. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood. 2005;106:3058–3061
  117. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J. 2005;19:1299–1301
  118. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, Woltering EA. Colchicine and 2-methoxyestradiol inhibit human angiogenesis. J. Surg. Res. 2005;125:104–108
  119. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N. Engl. J. Med. 2004;351:250–259
  120. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int. J. Cancer. 2004;110:117–124
  121. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369–3372
  122. Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, et al. Potential antagonism of tubulin-binding anticancer agents in combination therapies. Clin. Cancer Res. 2005;11:2720–2726
  123. Taraboletti G, Micheletti G, Giavazzi R, Riva A. IDN 5390: a new concept in taxane development. Anticancer Drugs. 2003;14:255–258
  124. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 2004;10:415–427
  125. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat. Rev. Cancer. 2005;5:423–435
  126. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001;61:6413–6422
  127. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. (U.S.A.). 2002;99:4349–4354
  128. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94:4143–4155
  129. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, et al. Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res. 2002;11:103–118
  130. Vallbo C, Wang W, Damber JE. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU Int. 2004;93:1339–1343
  131. Varbiro G, Veres B, Gallyas , Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic. Biol. Med. 2001;31:548–558
  132. Walss C, Kreisberg JI, Luduena RF. Presence of the betaII isotype of tubulin in the nuclei of cultured mesangial cells from rat kidney. Cell Motil. Cytoskelet. 1999;42:274–284
  133. Walss C, Kreisberg JI, Luduena RF. Mechanism of localization of betaII-tubulin in the nuclei of cultured rat kidney mesangial cells. Cell Motil. Cytoskelet. 2001;49:208–217
  134. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14:13–19
  135. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004;10:145–147
  136. Woltering EA, Lewis JM, Maxwell PJ, Frey DJ, Wang YZ, Rothermel J, et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann. Surg. 2003;237:790–800
  137. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin. Cancer Res. 2005;11:6678–6685
  138. Yeh IT, Ludueña RF. The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil. Cytoskelet. 2004;57:96–106

PII: S1368-7646(06)00023-9

doi: 10.1016/j.drup.2006.04.003

Drug Resistance Updates
Volume 9, Issue 1 , Pages 74-86 , February 2006

Article Tools

* Image Usage & Resolution